During the past decade, Consultorio de Investigación Clínica EMO SRL conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Consultorio de Investigación Clínica EMO SRL" are "Cardiovascular Disease" (2 trials), "Type 2 Diabetes" (2 trials), "Diabetes" (1 trials), "Obesity" (1 trials) and "Overweight" (1 trials). Many other conditions were trialed in "Consultorio de Investigación Clínica EMO SRL" in a lesser frequency.

Most popular intervention types in "Consultorio de Investigación Clínica EMO SRL" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "Insulin Efsitora Alfa" (3 trials), "Placebo" (3 trials), "Insulin Degludec" (2 trials), "bococizumab (PF-04950615)" (2 trials) and "Insulin Glargine (U100)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Consultorio de Investigación Clínica EMO SRL" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Consultorio de Investigación Clínica EMO SRL". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Consultorio de Investigación Clínica EMO SRL, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Consultorio de Investigación Clínica EMO SRL, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".